drugset
drugset / Trial / NCT04978506

A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated

NCT04978506 ↗

Phase 1 Completed 83 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

The main objectives of this trial are to investigate (1) safety, tolerability, pharmacokinetics and pharmacodynamics following multiple rising doses of BI 1569912; (2) tolerability of BI 1569912 in an up-titrating dosing scheme.

Timeline

Start
2021-09-03
Primary completion
2024-07-04
Completion
2024-07-04

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1569912 Unknown 2.5 mg Oral
Subject BI 1569912 Unknown 5 mg Oral
Subject BI 1569912 Unknown 10 mg Oral
Subject BI 1569912 Unknown 20 mg Oral
Subject BI 1569912 Unknown 30 mg Oral
Subject BI 1569912 Unknown 40 mg Oral

Indications

No indication recorded.